Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75
million new cases worldwide in 2015. The World Health Organization aims for a 90 …

The discovery of hepatitis C virus (HCV) in 1989 permitted basic research to unravel critical
components of a complex life cycle for this important human pathogen. HCV is a highly …

The contribution of humoral immune responses to spontaneous control of hepatitis C virus
(HCV) infection remains unclear. We assessed neutralizing antibody (nAb) responses …

The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a
global problem despite advances in antiviral therapeutics. Current treatments fail to prevent …

Hepatitis C virus (HCV) is a major cause of liver disease and hepatocellular carcinoma
worldwide. HCV establishes a chronic infection in the majority of cases. However, some …

Background & Aims Development of a prophylactic hepatitis C virus (HCV) vaccine will
require accurate and reproducible measurement of neutralizing breadth of vaccine-induced …

The development of a prophylactic vaccine for hepatitis C virus (HCV) remains a global
health challenge. Cumulative evidence supports the importance of antibodies targeting the …

For hepatitis C virus (HCV) and other highly variable viruses, broadly neutralizing mAbs are
an important guide for vaccine development. The development of resistance to anti-HCV …

Neutralizing antibodies (NAbs) targeting glycoprotein E2 are important for the control of
hepatitis C virus (HCV) infection. One conserved antigenic site (amino acids 412 to 423) is …

There are 3‐4 million new hepatitis C virus (HCV) infections yearly. The extensive
intergenotypic sequence diversity of envelope proteins E1 and E2 of HCV and shielding of …